Edgar Montánchez-Carazas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Edgar Montánchez-Carazas has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Germán Murillo Carrasco
Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), São Paulo 01246-000, Brazil, São Paulo, Brazil
1 shared publication - Cecilia Manrique-Sam
Faculty of Human Medicine, Universidad Católica de Santa María, Arequipa 04000, Peru
1 shared publication - Miguel Farfán-Delgado
Faculty of Human Medicine, Universidad Católica de Santa María, Arequipa 04000, Peru
1 shared publication - Tatiana Chavez-Arias
Escuela de Postgrado, Universidad Católica de Santa María, Arequipa 04013, Peru
1 shared publication - Yuma Ita-Balta
Universidad Católica de Santa Maria
1 shared publication
Latest Publications
- Open Access
- 29 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (4) , 184
Population-Specific Pharmacogenomic Profiling of NAT2, CYP2E1, and SLCO1B1 in Tuberculosis Patients from Southern Peru: A Feasibility Pilot Study
Tuberculosis (TB) remains a major public health challenge in Peru, where interindividual variability in treatment response and drug-induced hepatotoxicity may be influenced by host genetic background. This study aimed to characterize clinically relevant polymorphisms in NAT2, CYP2E1, and SLCO1B1 in a cohort of TB patients from Southern Peru, a genetically underrepresented Andean population. Thirty-five adults receiving first-line therapy (isoniazid and rifampicin) underwent targeted Sanger sequencing of key functional variants among these three genes. NAT2 acetylator phenotypes were predominantly intermediate (68.6%), followed by rapid (20%) and slow (11.4%) profiles, with high minor allele frequencies for rs1041983 and rs1801280. CYP2E1 functional promoter variants were infrequent, whereas SLCO1B1 exhibited notable allelic heterogeneity, suggesting potential variability in rifampicin transport. Comparative analysis with previously reported Peruvian data revealed regional differences in acetylator distribution, supporting population-specific pharmacogenomic stratification. Although clinical toxicity outcomes were not evaluated, the high prevalence of reduced acetylation genotypes suggests a substantial proportion of patients may benefit from genotype-informed isoniazid dosing strategies. These findings provide foundational data for implementing precision medicine approaches using affordable and targeted technologies in TB management within Andean populations and support the integration of pharmacogenomics into national TB control programs.
- 29 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (4) , 184
Open AccessPopulation-Specific Pharmacogenomic Profiling of NAT2, CYP2E1, and SLCO1B1 in Tuberculosis Patients from Southern Peru: A Feasibility Pilot Study
Tuberculosis (TB) remains a major public health challenge in Peru, where interindividual variability in treatment response and drug-induced hepatotoxicity may be influenced by host genetic background. This study aimed to characterize clinically relevant polymorphisms in NAT2, CYP2E1, and SLCO1B1 in a cohort of TB patients from Southern Peru, a genetically underrepresented Andean population. Thirty-five adults receiving first-line therapy (isoniazid and rifampicin) underwent targeted Sanger sequencing of key functional variants among these three genes. NAT2 acetylator phenotypes were predominantly intermediate (68.6%), followed by rapid (20%) and slow (11.4%) profiles, with high minor allele frequencies for rs1041983 and rs1801280. CYP2E1 functional promoter variants were infrequent, whereas SLCO1B1 exhibited notable allelic heterogeneity, suggesting potential variability in rifampicin transport. Comparative analysis with previously reported Peruvian data revealed regional differences in acetylator distribution, supporting population-specific pharmacogenomic stratification. Although clinical toxicity outcomes were not evaluated, the high prevalence of reduced acetylation genotypes suggests a substantial proportion of patients may benefit from genotype-informed isoniazid dosing strategies. These findings provide foundational data for implementing precision medicine approaches using affordable and targeted technologies in TB management within Andean populations and support the integration of pharmacogenomics into national TB control programs.